Kenvue Inc. $KVUE Stock: Jefferies Financial Group Inc. Reduces Stake

Jefferies Financial Group Inc. trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 28.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,000,000 shares of the company’s stock after selling 400,048 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Kenvue were worth $17,660,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Johnson Financial Group Inc. purchased a new stake in Kenvue during the second quarter worth $26,000. GK Wealth Management LLC bought a new stake in Kenvue during the 3rd quarter valued at $27,000. CoreCap Advisors LLC increased its holdings in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares during the period. Bell Investment Advisors Inc purchased a new position in shares of Kenvue in the 2nd quarter valued at $35,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Kenvue in the 3rd quarter valued at $36,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $19.31 on Thursday. The business’s 50-day simple moving average is $18.43 and its two-hundred day simple moving average is $18.27. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The company has a market cap of $37.09 billion, a PE ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a fifty-two week low of $14.06 and a fifty-two week high of $20.13.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. During the same period last year, the business posted $0.28 earnings per share. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is 95.45%.

Wall Street Analyst Weigh In

Several research firms have recently commented on KVUE. HSBC reduced their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. UBS Group lifted their target price on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research note on Monday, November 2nd. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Ten research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.29.

About Kenvue

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.